Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial
Fabio Efficace(Fondazione Gimema Onlus), Michael Lübbert(University of Freiburg), Robin Foà(Sapienza University of Rome), Walter J. F. M. van der Velden(Radboud University Nijmegen), Frédéric Baron(University of Liège), Paola Fazi(Fondazione Gimema Onlus), Eduardus F. M. Posthuma(Leiden University Medical Center), Sylvain Chantepie(Centre Hospitalier Universitaire de Caen Normandie), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Gerwin Huls(University Medical Center Groningen), Corneel Coens(European Organisation for Research and Treatment of Cancer), Andrea Mengarelli(Istituti di Ricovero e Cura a Carattere Scientifico), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stephan Fuhrmann(Helios Hospital Berlin-Buch), Andreas Neubauer(RWTH Aachen University), Stefan Suciu(European Organisation for Research and Treatment of Cancer), Radovan Vrḫovac(University Hospital Centre Zagreb), Laimonas Griškevičius(Vilnius University), Marco Vignetti(Fondazione Gimema Onlus), Richard Noppeney(Essen University Hospital), Martina Crysandt(RWTH Aachen University), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Pierre W. Wijermans(Radboud University Nijmegen), Olivier Legrand(Inserm), Anna Candoni(University of Udine), Adriano Venditti(University of Rome Tor Vergata), Mario Luppi(University of Modena and Reggio Emilia)
Cited by 18
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k